CPP aims to be a global leader in the development of pharmaceutical agents,
acting alone or in combinations, that will effectively and safely reduce the risk of
cancers in patients with genetic risk factors, such as familial adenomatous
polyposis (FAP) or prior conditions that increase risk of cancer, such as colon
polyps, Barrett's esophagus, prostatic intraepithelial neoplasia and dysplastic
nevi of the skin.
CPP is seeking $20 million in equity financing to support its efforts over the next three years. This will allow the Company to complete a pivotal trial in Familial Adenomatous Polyposis (FAP) and file a New Drug Application (NDA) with the FDA. The financing effort will also support another NDA/registration-trial in Colon Adenoma Therapy (CAT) that will be co-sponsored with the National Cancer Institute (NCI) and conducted by the Southwest Oncology Group (SWOG). CPP will also support a PI/II Neuroblastoma (NB) trial and a clinical urinary biomarker trial, and will contribute to additional NCI-funded trials.
We believe the time is right to apply "Risk Reduction" paradigms to cancer because of the ...
Potential to Impact Cancer Death Rates in a Significant Way
Biomarkers and Critical Path Initiative
CPP is uniquely positioned to make it happen.
Please contact Jeffrey Jacob at firstname.lastname@example.org or
(520) 908-7774 for more information.
UA Spin-off to Test Cancer Prevention . . .
CPP Receives Positive . . .
Success in Clinical Trials . . .
Biotech Firms Get Funding . . .
Tucson Cancer Prevention Firm is BioIndustry Winner . . .
Company Gets U.S. Grant for Research of Cancer Drug . . .
CPP Wins Fast Start Award and Federal Grant . . .